MET and lung carcinoma: In patients with non-squamous NSCLC, the rate of MET mutations ranges from 2–4% (15, 19, 20), although such mutations are clearly overrepresented among older adults, in whom the prevalence is comparable to that observed in patients with ALK-rearranged lung cancer (21).